Login to Your Account

Depomed snaps up Nautilus migraine drug for $48.7M

By Catherine Shaffer
Staff Writer

Thursday, December 19, 2013

Depomed Inc. boosted its pain portfolio with the purchase of Nautilus Neurosciences Inc.’s migraine drug, Cambia (diclofenac potassium for oral solution) for $48.7 million. Nautilus is eligible for an additional $5 million payment based on achievement of sales milestones. Cambia is the only single agent non-steroidal anti-inflammatory specifically indicated for migraine, with $18 million in sales over the past 3 months.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription